Powder: -20°C for 3 years | In solvent: -80°C for 1 year
dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis.
説明 | dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis. |
ターゲット&IC50 | BET:430 nM (EC50) |
In vitro | dBET1 induced a potent and superior inhibitory effect on MV4;11 cell proliferation at 24 hours (measured by ATP content, IC50 = 0.14 μM, compared to IC50 = 1.1 μM with JQ1) consistent with the reported, pronounced inhibitory effect of RNA silencing of BRD4 in this and other models of MLL-rearranged leukemia. |
分子量 | 785.27 |
分子式 | C38H37ClN8O7S |
CAS No. | 1799711-21-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL
H2O: Insoluble
Ethanol: 5 mg/mL
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
dBET1 1799711-21-9 Chromatin/Epigenetic Epigenetic Reader Domain inhibit PROTACs Inhibitor dBET 1 dBET-1 inhibitor